Skip to search formSkip to main contentSkip to account menu

tasidotin

A third generation, synthetic, water-soluble, pentapeptide analog of the marine depsipeptide dolastatin 15, with potential antimitotic and… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ILX 651tasidotin hydrochloride
Microtubule ProcessNCIt Antineoplastic Agent Terminology

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Anticancer compounds from cyanobacterium Lyngbya species: a review
The use of synthetic anticancer drugs and other methods followed in cancer therapy have several side effects; and ineffective… 
2009
2009
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
PurposeTo evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in… 
Highly Cited
2007
Highly Cited
2007
Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate.
Tasidotin (ILX-651), an orally active synthetic microtubule-targeted derivative of the marine depsipeptide dolastatin-15, is… 
2006
2006
Preclinical and Clinical Drug Development of Tasidotin, a Depsi‐Pentapeptide Oncolytic Agent
2005
2005
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651… 
Review
2005
Review
2005
Tasidotin HCl (Genzyme).
2005
2005
Plaunotol inhibits gastric cancer cells by induction of apoptosis
5903 BACKGROUND AND AIM: Plaunotol, a kind of isoprenoid, is an anti-gastric ulcer agent, available for clinical use since more… 
2005
2005
APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors
Purpose:To determine themaximum tolerated dose, dose-limiting toxicity, andpharmacokinetics of the dolastatin-15 analogue… 
2005
2005
Tasidotin HCl (formerly ILX651), a tubulin-binding dolastatin-15 analog, demostrates a wide spectrum of In Vivo antitumor activity
Proc Amer Assoc Cancer Res, Volume 46, 2005 5876 Tasidotin HCl is a synthetic pentapeptide derivative of dolastatin-15 with a… 
2005
2005
In vivo antitumor effect of Tasidotin HCl (formerly ILX651), a dolastatin-15 analog with a novel mechanism of action, against the PANC-1 and MiaPaCa human pancreatic tumor xenograft models
5904 Tasidotin HCl is a synthetic pentapeptide derivative of dolastatin-15 with a unique mechanism of action that potentially… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)